Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, David Allsup et al.|New England Journal of Medicine|2025Cited by 26
Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patientsCharlotte Evans, Talha Munir, Surita Dalal et al.|Blood|2025Cited by 2